172 related articles for article (PubMed ID: 27057638)
1. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.
Pusceddu S; De Braud F; Lo Russo G; Concas L; Femia D; Vernieri C; Indini A; Formisano B; Buzzoni R
Oncotarget; 2016 Jul; 7(28):44841-44847. PubMed ID: 27057638
[TBL] [Abstract][Full Text] [Related]
2. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
3. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
4. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):11-3. PubMed ID: 27168106
[No Abstract] [Full Text] [Related]
6. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
7. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
8. Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study).
Shimoyama R; Hijioka S; Mizuno N; Ogawa G; Kataoka T; Katayama H; Machida N; Honma Y; Boku N; Hamaguchi T; Fukuda H; Terashima M; Kanemitsu Y; Furuse J;
Pancreatology; 2020 Sep; 20(6):1183-1188. PubMed ID: 32798144
[TBL] [Abstract][Full Text] [Related]
9. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
12. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials.
Fazio N; Carnaghi C; Buzzoni R; Valle JW; Herbst F; Ridolfi A; Strosberg J; Kulke MH; Pavel ME; Yao JC
Cancer; 2021 Aug; 127(15):2674-2682. PubMed ID: 33857327
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial.
Pavel ME; Becerra C; Grosch K; Cheung W; Hasskarl J; Yao JC
Clin Pharmacol Ther; 2017 Apr; 101(4):462-468. PubMed ID: 28032910
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L; Ito T; Jensen RT
Expert Opin Pharmacother; 2018 Jun; 19(8):909-928. PubMed ID: 29757017
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
Fazio N; Buzzoni R; Delle Fave G; Tesselaar ME; Wolin E; Van Cutsem E; Tomassetti P; Strosberg J; Voi M; Bubuteishvili-Pacaud L; Ridolfi A; Herbst F; Tomasek J; Singh S; Pavel M; Kulke MH; Valle JW; Yao JC
Cancer Sci; 2018 Jan; 109(1):174-181. PubMed ID: 29055056
[TBL] [Abstract][Full Text] [Related]
17. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey.
Falconi M; Fazio N; Ferone D; Versari A
Expert Opin Pharmacother; 2020 Dec; 21(18):2317-2324. PubMed ID: 32990061
[TBL] [Abstract][Full Text] [Related]
18. Role of everolimus in the treatment of advanced neuroendocrine tumor: a meta-analysis of randomized trials.
Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
J BUON; 2019; 24(1):368-373. PubMed ID: 30941993
[TBL] [Abstract][Full Text] [Related]
19. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies.
Chan DL; Yao JC; Carnaghi C; Buzzoni R; Herbst F; Ridolfi A; Strosberg J; Kulke MH; Pavel M; Singh S
Pancreas; 2021 Feb; 50(2):130-137. PubMed ID: 33560090
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.
Pavel ME; Chen D; He W; Cushman S; Voi M; de Vries EGE; Baudin E; Yao JC
Pancreas; 2017 Jul; 46(6):751-757. PubMed ID: 28609362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
